Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06276556 · ClinicalTrials.gov registry record · Phase 2
Extension Study of ABP-671 in Participants With Gout
A Phase 2 study, sponsored by Atom Therapeutics Co..
- Terminated
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT06276556: Clinical Trial Phase 2 study, sponsored by Atom Therapeutics Co..
NCT06276556 is a Phase 2 study that was terminated before completion, run by Atom Therapeutics Co.. The registered enrollment target is 43 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06276556, a Phase 2 study, was terminated before completion, sponsored by Atom Therapeutics Co..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
The primary objectives of this study are to assess the safety, tolerability, and efficacy of ABP-671 in lowering serum uric acid (sUA) in participants with gout who roll over from Study ABP-671-301 after they complete the double-blind 28-week Treatment Period of Part 1 (Phase 2b) or Part 2 (Phase 3).
Interventions
- DRUG Allopurinol
- DRUG ABP-671
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2024-04-22 |
| Est. Completion | 2024-09-05 |
| Phase | Phase 2 |
Why NCT06276556 stopped before completion
NCT06276556 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 2 interventions - of which Allopurinol is the first listed.
NCT06276556 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06276556 about?
NCT06276556 is a clinical study titled "Extension Study of ABP-671 in Participants With Gout". The primary objectives of this study are to assess the safety, tolerability, and efficacy of ABP-671 in lowering serum uric acid (sUA) in participants with gout who roll over from Study ABP-671-301 after they complete the double-blind 28-week Treatment Period of Part 1 (Phase 2b) or Part 2 (Phase 3)...
What is the current status of trial NCT06276556?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2024-04-22. Estimated completion is 2024-09-05.
What interventions are being tested in trial NCT06276556?
The interventions under investigation include: Allopurinol (DRUG), ABP-671 (DRUG).
Who is sponsoring clinical trial NCT06276556?
This trial is sponsored by Atom Therapeutics Co., which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06276556's enrollment target sits among peer trials
43 1332nd of 2000 higher than 662 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI